



**100mg losartan potassium / 12.5mg  
hydrochlorothiazide (COZAAR<sup>®</sup> – Comp 100/12.5)**

**Merck Sharp & Dohme Limited**

**June 2008**

**Appraisal notice to NHS Wales**

**100mg losartan potassium / 12.5mg hydrochlorothiazide (COZAAR<sup>®</sup> – Comp 100/12.5) has not been endorsed for use within NHS Wales for the treatment of hypertension in patients whose blood pressure is not adequately controlled on hydrochlorothiazide or losartan monotherapy.**

**The holder of the marketing authorisation has not made a submission to AWMSG for the appraisal of 100mg losartan potassium / 12.5mg hydrochlorothiazide (COZAAR<sup>®</sup> – Comp 100/12.5) in the above indication. As a result, AWMSG cannot advise the Minister for Health and Social Services whether this medicine should be available for use within NHS Wales.**

**Advice context:**

No part of this advice may be used without the whole of the advice being quoted in full.

AWMSG takes into account the NICE future work programme when considering whether a product will be appraised. AWMSG does not normally consider appraising a product if NICE intends to publish their final appraisal of the same product within a 18 month period from receipt of Form B. i.e. approx 12 months from the projected AWMSG appraisal date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

This notice is provided for information to NHS Wales. In the absence of guidance issued by NICE or AWMSG individual clinicians should exercise their clinical judgement, unless there is evidence to justify not doing so in the light of particular circumstances of an individual patient.

**Chairman  
All Wales Medicines Strategy Group**

**June 2008**